Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.
“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Moleculin Biotech reported a net loss of $27.0 million for the nine months ended September 30, 2026, compared to a $49.1 million loss in the prior year period. The company ended the quarter with $7.3 million in cash and cash equivalents, supported by $20.3 million in net cash provided by financing activities during the year.
Moleculin Biotech announced the grant of Australian Patent No. 2020303572, which covers the preparation of preliposomal Annamycin lyophilizate. The patent was granted jointly to Moleculin and The Board of Regents of The University of Texas System, strengthening the company's international intellectual property portfolio for its lead drug candidate, Annamycin.
Counterparty
The Board of Regents of The University of Texas System
Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.
Moleculin Biotech announced that interim data from its pivotal Phase 2/3 trial (MB-108) of Annamycin for relapsed or refractory AML will be presented at the 2026 ASH Annual Meeting. The data showed complete remission rates of 43% and 36% in the treatment arms compared to 12% for placebo, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended the study continue without amendment.
Moleculin Biotech has completed patient dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML). The company remains on track to report comprehensive data from the 90-patient Part A population in the first quarter of 2027, which will inform dose selection for Part B of the trial.
Moleculin Biotech announced a 1-for-20 reverse stock split of its common stock, effective October 20, 2026. The split will reduce the number of outstanding shares from approximately 20.91 million to approximately 1.05 million to satisfy Nasdaq listing requirements. The company's common stock will continue to trade under the ticker 'MBRX' with a new CUSIP number.
Moleculin Biotech, Inc. has updated its corporate investor presentation and posted the deck to its website. The presentation, filed as Exhibit 99.1, provides a strategic and operational update on the company's clinical pipeline and corporate milestones.
Moleculin Biotech held its 2026 Annual Meeting of Stockholders where shareholders elected five directors and ratified Grant Thornton LLP as the independent auditor. Stockholders also approved an amendment to the 2024 Equity Plan to increase the authorized shares by 3,861,894 and passed a non-binding advisory resolution on executive compensation.
Moleculin Biotech, Inc. has filed a formal corporate investor presentation as an exhibit to its 8-K. The presentation, dated October 5, 2026, is being used for corporate updates and has been posted to the company's website. The filing was made under Item 7.01 (Regulation FD Disclosure) to provide current information to investors and analysts.
Moleculin Biotech has completed and closed enrollment for Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (R/R AML). The company enrolled 89 subjects and remains on track for a comprehensive data readout in the first quarter of 2027. The final Part A dataset is expected to provide efficacy insights across both 'fit' and 'unfit' patient populations, with an estimated 50/50 split between those previously treated with intensive chemotherapy versus venetoclax-based regimens.
Moleculin Biotech announced the peer-reviewed publication of a pooled cardiac safety analysis of its drug candidate Annamycin in Frontiers in Cardiovascular Medicine. The analysis of 90 patients across five clinical trials found no clinical or subclinical evidence of cardiotoxicity, even at cumulative doses exceeding traditional anthracycline limits.
Counterparty
Cleveland Clinic
“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program. For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Moleculin Biotech announced new preclinical data for its lead drug candidate, Annamycin, showing that its antitumor activity in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity. The findings, presented at the AACR Conference on Pancreatic Cancer, suggest the drug may turn immunologically 'cold' tumors 'hot,' potentially enabling new combination therapy approaches.
Moleculin Biotech raised $0.48 million in gross proceeds through the issuance of 888,400 shares under its at-the-market (ATM) offering program in September 2026. The issuance triggered an anti-dilution provision in the company's Series I Warrants, reducing their exercise price from $0.75 to $0.51 per share.
Moleculin Biotech received a Staff Determination Letter from Nasdaq notifying the company that its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days. Because the company already performed a reverse stock split within the last year, it is ineligible for the standard 180-day grace period and faces immediate delisting unless it successfully appeals to the Nasdaq Hearings Panel.